Lyra Therapeutics, Inc. (LYRA)
Sector: Biotechnology
Industry: Biotechnology
Lyra Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 0.0300 | 0.0300 | 0.0300 | 0.0300 | 8,139 |
| Nov 5, 2026 | 0.0300 | 0.1900 | 0.0300 | 0.1900 | 401 |
| Nov 2, 2026 | 0.0300 | 0.1900 | 0.0300 | 0.1900 | 403 |
| Oct 27, 2026 | 0.0300 | 0.1900 | 0.0300 | 0.1900 | 10,110 |
| Oct 19, 2026 | 0.0300 | 0.1900 | 0.0300 | 0.1900 | 4,321 |
| Oct 13, 2026 | 0.0510 | 0.1900 | 0.0510 | 0.1900 | 420 |
| Oct 9, 2026 | 0.0300 | 0.1900 | 0.0300 | 0.1900 | 2,100 |
| Oct 8, 2026 | 0.0300 | 0.1950 | 0.0300 | 0.1950 | 2,102 |
| Oct 5, 2026 | 0.1447 | 0.1900 | 0.1423 | 0.1900 | 317 |
| Oct 2, 2026 | 0.1500 | 0.1500 | 0.1500 | 0.1500 | 348 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Withholding/Transfer | 640 | -- | May 14, 2026 | |
| Principal Financial Officer | Withholding/Transfer | 667 | -- | Apr 1, 2026 | |
| Principal Executive Officer | Withholding/Transfer | 2.0K | -- | Apr 1, 2026 | |
| Principal Financial Officer | Sale | 769 | $2.6K | Jan 6, 2026 | |
| Principal Executive Officer | Sale | 1.7K | $5.7K | Jan 6, 2026 | |
| 10% Owner | Sale | 28.6K | $111.5K | Nov 13, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Palasis Maria Principal Executive Officer, Director | 1.1M | -- | FORM 4 |
Cavalier Jason Principal Financial Officer | 517.9K | -- | FORM 4 |
SABBY MANAGEMENT, LLC · filed Jan 2026 | 175.2K | 9.9% | 13G |
Samsara BioCapital, L.P. · may incl. warrants· stale · filed Nov 2024 | 65.6K | 5.0% | 13G |
Pura Vida Investments, LLC · filed Feb 2024 | 32.3K | 3.1% | 13G |
Venrock Healthcare Capital Partners II, L.P. · may incl. warrants· stale · filed Nov 2024 | 24.1K | 1.8% | 13G |
Nantahala Capital Management, LLC · may incl. warrants· stale · filed Nov 2024 | 14.0K | 1.1% | 13G |
COMERICA BANK | 23 | -- | 13F |
Insiders
- Smith W BradfordDirector
- Cavalier JasonPrincipal Financial Officer
- Palasis MariaPrincipal Executive Officer
- PERCEPTIVE ADVISORS LLC10% Owner
- MERRIFIELD C ANNDirector
- TOBIN JAMES RDirector
- snyderman nancy lynn MDDirector
- Waksal HarlanExecutive Chair
Top institutional holders
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.
Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.
It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.
The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
based on 11.24M shares outstanding
30d Avg
4.12K
60d Avg
2.15K
90d Avg
1.53K
Lyra Therapeutics, Inc. (OTC: LYRA) traded at $0.0300 on Nov 16, 2026, down 84.21% from the previous close of $0.1900. 52-week range: $0.0004 to $4.59. The company is in the Healthcare sector (Biotechnology).